Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Change in Account Payables: 2010-2025

Historic Change in Account Payables for Anika Therapeutics (ANIK) over the last 13 years, with Sep 2025 value amounting to $231,000.

  • Anika Therapeutics' Change in Account Payables rose 107.87% to $231,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$956,000, marking a year-over-year increase of 11.23%. This contributed to the annual value of -$2.5 million for FY2024, which is 22681.82% down from last year.
  • As of Q3 2025, Anika Therapeutics' Change in Account Payables stood at $231,000, which was up 120.75% from -$1.1 million recorded in Q2 2025.
  • Anika Therapeutics' 5-year Change in Account Payables high stood at $1.4 million for Q4 2022, and its period low was -$2.9 million during Q3 2024.
  • Over the past 3 years, Anika Therapeutics' median Change in Account Payables value was -$121,000 (recorded in 2024), while the average stood at -$304,727.
  • As far as peak fluctuations go, Anika Therapeutics' Change in Account Payables spiked by 515.00% in 2022, and later tumbled by 911.72% in 2024.
  • Over the past 5 years, Anika Therapeutics' Change in Account Payables (Quarterly) stood at -$398,000 in 2021, then soared by 459.80% to $1.4 million in 2022, then fell by 8.66% to $1.3 million in 2023, then crashed by 109.25% to -$121,000 in 2024, then skyrocketed by 107.87% to $231,000 in 2025.
  • Its last three reported values are $231,000 in Q3 2025, -$1.1 million for Q2 2025, and $47,000 during Q1 2025.